Egrifta Post-marketing Study On Diabetic Retinopathy Will Include CV Outcomes

FDA’s decision to require a post-approval clinical trial evaluating the cardiovascular effects of Theratechnologies’ HIV lipodystrophy drug Egrifta shows the agency has overcome concerns – both its own and those of its advisory committee – that such a study could not be feasibly and ethically conducted.